Novogen Limited (KZIA)
(Delayed Data from NSDQ)
$0.32 USD
-0.01 (-1.70%)
Updated Sep 20, 2024 03:44 PM ET
After-Market: $0.32 0.00 (-1.45%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KZIA 0.32 -0.01(-1.70%)
Will KZIA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KZIA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KZIA
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
KZIA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novogen Limited (KZIA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now
Other News for KZIA
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
Kazia Therapeutics enters into licensing agreement with QIMR Berghofer
Kazia Therapeutics executes licensing agreement with QIMR Berghofer Medical
Kazia Therapeutics files to sell $100M of American Depositary Shares
Kazia Therapeutics files to sell $100M of American Depositary Shares